Brainstorm Cell Therapeutics Inc. Stock Forecast NASDAQ:BCLI

Price Target and Analyst Ratings

Most Recent Rating

Maxim Group is very positive about BCLI and gave it a "Hold - Buy" rating on February 04, 2021. The price target was set to $12.00.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-02-04	Hold - Buy	Upgraded by	Maxim Group	$7.88	$12.00
2020-11-17	Buy - Hold	Downgraded by	Maxim Group	$4.02
2020-07-08	Buy	Target Raised by	Maxim Group	$12.83	$9.00 → $20.00

BCLI Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -7.61% during the next 3 months and, with a 90% probability hold a price between $2.88 and $3.61 at the end of this 3-month period.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-23	$3.11	$3.51	$3.91
2021-09-24	$3.10	$3.50	$3.90
2021-09-27	$3.10	$3.50	$3.90
2021-09-28	$3.09	$3.49	$3.89
2021-09-29	$3.09	$3.49	$3.89
2021-09-30	$3.08	$3.48	$3.88
2021-10-01	$3.08	$3.48	$3.88
2021-10-04	$3.07	$3.47	$3.87
2021-10-05	$3.07	$3.47	$3.87
2021-10-06	$3.06	$3.46	$3.86
2021-10-07	$3.06	$3.46	$3.85
2021-10-08	$3.05	$3.45	$3.85
2021-10-11	$3.05	$3.45	$3.84
2021-10-12	$3.04	$3.44	$3.84
2021-10-13	$3.04	$3.44	$3.83
2021-10-14	$3.03	$3.43	$3.83
2021-10-15	$3.03	$3.43	$3.82
2021-10-18	$3.02	$3.42	$3.82
2021-10-19	$3.02	$3.42	$3.81
2021-10-20	$3.01	$3.41	$3.81
2021-10-21	$3.01	$3.41	$3.80
2021-10-22	$3.00	$3.40	$3.80
2021-10-25	$3.00	$3.40	$3.79
2021-10-26	$2.99	$3.39	$3.79
2021-10-27	$2.99	$3.38	$3.78
2021-10-28	$2.98	$3.38	$3.78
2021-10-29	$2.98	$3.37	$3.77
2021-11-01	$2.97	$3.37	$3.77
2021-11-02	$2.97	$3.36	$3.76
2021-11-03	$2.96	$3.36	$3.76

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The companys NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cell... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!